Návratnost jmění společnosti Intercept Pharmaceuticals Inc

Jaká je hodnota metriky Návratnost jmění společnosti Intercept Pharmaceuticals Inc?

Hodnota metriky Návratnost jmění společnosti Intercept Pharmaceuticals Inc je -82.24%

Jaká je definice metriky Návratnost jmění?



Návratnost kapitálu (Return on equity - ROE) je rentabilita vlastního kapitálu. Vypočítá se vydělením čistého příjmu za fiskální rok vlastním kapitálem.

The return on equity (ROE) ROE is a measure of how well a company uses investments to generate earnings growth. ROE is used for comparing the performance of companies in the same industry. It indicated the management's ability to generate income from the equity available to it. ROEs of 15-20% are generally considered good. ROEs are also a factor in stock valuation, in association with other financial ratios. In general, stock prices are influenced by earnings per share (EPS), so that stock of a company with a 20% ROE will generally cost twice as much as one with a 10% ROE.

Návratnost jmění společností v sektoru Health Care sektor na NASDAQ ve srovnání se společností Intercept Pharmaceuticals Inc

Čemu se věnuje společnost Intercept Pharmaceuticals Inc?

we are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, including primary biliary cholangitis (pbc), nonalcoholic steatohepatitis (nash), primary sclerosing cholangitis (psc) and biliary atresia. in a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with progressive, non-viral liver disease. we are committed to improving patients’ lives and addressing the liver community’s most pressing needs. our corporate headquarters is located in new york, and we have additional offices in san diego, london and perugia. for more information about intercept, please visit our website at: www.interceptpharma.com and follow us on twitter at: @interceptpharma.

Firmy s metrikou návratnost jmění podobnou společnosti Intercept Pharmaceuticals Inc